RGDX Key Stats
- Response Genetics, Inc. Announces Presentations at the American Society of Clini... May 20
- Morning Market Movers Benzinga May 16
- Response Genetics (RGDX) Surges on Blue Shield of California Contract Street Insider May 16
- A Peek Into The Market Before The Trading Starts Benzinga May 16
- Response Genetics, Inc. Announces Contract With Blue Shield of California Benzinga May 16
- Emerging Biomarker Companies Redux: Positioned For Growth May 15
- RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report May 15
- Response Genetics' CEO Discusses F1Q13 Earnings Results - Earnings Call Transcri... May 14
- Response Genetics, Inc. (RGDX) Beats Q1 Loss Views Street Insider May 14
- Q1 2013 Response Genetics Earnings Release - Before Market Open May 14
RGDX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Response Genetics is down 6.67% over the last year vs S&P 500 Total Return up 31.95%, BG Medicine down 55.39%, and Agilent Technologies up 21.99%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for RGDX
Pro Report PDF for RGDX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download RGDX Pro Report PDF
Pro Strategies Featuring RGDX
Did Response Genetics make it into our Pro Portfolio Strategies?